← Back to Home

4basebio partners with TriLink to link DNA and mRNA manufacturing for a Phase I cell therapy trial

A cell therapy program at an unnamed multinational pharmaceutical company will use synthetic DNA and outsourced mRNA manufacturing services. The collaboration brings a novel starting material into clinical supply, but manufacturing benefits and the therapy’s performance remain to be verified by data.

By SURL BioNews

Bringing a cell therapy into human trials requires not only a therapeutic design but also a manufacturing process that can provide a reliable supply. On September 28, 2026, 4basebio and TriLink BioTechnologies announced a collaboration to link the production of synthetic DNA starting material and mRNA drug substance for an upcoming Phase I cell therapy trial at an unnamed multinational pharmaceutical company.

According to 4basebio’s announcement and a report published by Outsourced Pharma on the same day, 4basebio will supply clinical-grade opDNA synthetic DNA starting material. TriLink, part of Maravai LifeSciences, will serve as the contract development and manufacturing organization responsible for producing the mRNA drug substance. The collaboration also extends 4basebio’s existing business relationship with the pharmaceutical company into a cell therapy program.

The two companies’ respective roles connect the manufacturing steps from DNA template to mRNA. opDNA is manufactured enzymatically, while TriLink will use its CleanCap technology to add a cap structure as mRNA is generated through transcription. The announcement did not specify the role of these mRNAs in the cell therapy or disclose the cell type or therapeutic target.

From a manufacturing perspective, the arrangement centers on integrating a novel DNA starting material into the manufacturing system selected by the customer. 4basebio said opDNA can be integrated into existing workflows and positioned it as an alternative to plasmid DNA. However, the announcement provided no comparisons of yield, purity, batch consistency or cost for the program, so the extent of any improvement from this integration cannot yet be quantified.

The information currently available is also insufficient to assess the therapy itself. The pharmaceutical company’s name, indication, trial size and exact start date have not been disclosed. The announcement refers to preparing supply for an upcoming Phase I trial; it does not confirm that any participants have received treatment, and it provides no human safety or efficacy results.

The parties did not disclose financial terms, so the announcement does not provide a basis for determining the size of the order or subsequent revenue. The collaboration represents a practical arrangement in which a synthetic DNA supplier and an mRNA manufacturer jointly support early clinical development. Whether it can shorten manufacturing timelines, maintain consistent quality and ultimately help advance the therapy remains to be answered by subsequent manufacturing and clinical data.

References

  1. The Manila Times
  2. 4basebio
  3. Outsourced Pharma